Michael R. Vredenburg, Ph.D. - Publications
Affiliations: | 2005 | State University of New York, Buffalo, Buffalo, NY, United States |
Area:
PharmacologyYear | Citation | Score | |||
---|---|---|---|---|---|
2007 | Brooks TA, O'Loughlin KL, Minderman H, Bundy BN, Ford LA, Vredenburg MR, Bernacki RJ, Priebe W, Baer MR. The 4′-O-benzylated doxorubicin analog WP744 overcomes resistance mediated by P-glycoprotein, multidrug resistance protein and breast cancer resistance protein in cell lines and acute myeloid leukemia cells Investigational New Drugs. 25: 115-122. PMID 17072745 DOI: 10.1007/S10637-006-9018-3 | 0.403 | |||
2004 | Ramnath N, Hamm J, Schwartz G, Holden S, Eckhardt SG, Vredenburg MR, Bernacki RJ, Lathia C, Kanter P, Creaven PJ. A phase I and pharmacokinetic study of BAY59: a novel taxane. Oncology. 67: 123-9. PMID 15539916 DOI: 10.1159/000080998 | 0.449 | |||
2001 | Vredenburg MR, Ojima I, Veith J, Pera P, Kee K, Cabral F, Sharma A, Kanter P, Greco WR, Bernacki RJ. Effects of orally active taxanes on P-glycoprotein modulation and colon and breast carcinoma drug resistance. Journal of the National Cancer Institute. 93: 1234-45. PMID 11504769 DOI: 10.1093/Jnci/93.16.1234 | 0.554 | |||
Show low-probability matches. |